{"transactions":[{"id":724684,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-29T20:41:06.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 6,000 non-qualified stock options (\"Stock Options\") exercisable solely into Class A common stock (\"Common Stock\") of vTv Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 26, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's 2024 Equity Incentive Plan. The Stock Options have a strike price of $35.08 per share and vest on the earlier of June 26, 2027 or the date of the 2027 annual general meeting of the Issuer's shareholders, subject to Dr. Cheong's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 26, 2036."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 6,000 non-qualified stock options (\"Stock Options\") exercisable solely into Class A common stock (\"Common Stock\") of vTv Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 26, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's 2024 Equity Incentive Plan. The Stock Options have a strike price of $35.08 per share and vest on the earlier of June 26, 2027 or the date of the 2027 annual general meeting of the Issuer's shareholders, subject to Dr. Cheong's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 26, 2036."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Cheong serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Dr. Cheong does not have a right to any of the Issuer's securities issued as compensation for his service on the Board, and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents a single grant to Dr. Cheong of 6,000 Stock Options on Table II. This grant of 6,000 Stock Options for Dr. Cheong is reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":6000,"derivative":{"exercise_price":35.08,"expiration_date":"2036-06-26","underlying":"Class A common stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001193125-26-288602","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526288602/ownership.xml","form_type":"4"}},{"id":724683,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-29T20:41:06.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 6,000 non-qualified stock options (\"Stock Options\") exercisable solely into Class A common stock (\"Common Stock\") of vTv Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 26, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's 2024 Equity Incentive Plan. The Stock Options have a strike price of $35.08 per share and vest on the earlier of June 26, 2027 or the date of the 2027 annual general meeting of the Issuer's shareholders, subject to Dr. Cheong's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 26, 2036."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 6,000 non-qualified stock options (\"Stock Options\") exercisable solely into Class A common stock (\"Common Stock\") of vTv Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 26, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's 2024 Equity Incentive Plan. The Stock Options have a strike price of $35.08 per share and vest on the earlier of June 26, 2027 or the date of the 2027 annual general meeting of the Issuer's shareholders, subject to Dr. Cheong's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 26, 2036."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Cheong serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Dr. Cheong does not have a right to any of the Issuer's securities issued as compensation for his service on the Board, and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents a single grant to Dr. Cheong of 6,000 Stock Options on Table II. This grant of 6,000 Stock Options for Dr. Cheong is reported for each of the Funds as each has an indirect pecuniary interest in such securities."}],"balance_after":6000,"derivative":{"exercise_price":35.08,"expiration_date":"2036-06-26","underlying":"Class A common stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001193125-26-288602","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526288602/ownership.xml","form_type":"4"}},{"id":723854,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2026-06-29T20:10:19.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":35.08,"value":210480.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting."}],"balance_after":16000,"derivative":{"exercise_price":35.08,"expiration_date":"2036-06-26","underlying":"Class A Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001238403-26-000006","document":"wk-form4_1782763816.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1238403/000123840326000006/wk-form4_1782763816.xml","form_type":"4"}},{"id":723819,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2026-06-29T20:09:54.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":35.08,"value":210480.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting."}],"balance_after":16983,"derivative":{"exercise_price":35.08,"expiration_date":"2036-06-26","underlying":"Class A Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001253170-26-000008","document":"wk-form4_1782763791.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253170/000125317026000008/wk-form4_1782763791.xml","form_type":"4"}},{"id":723696,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34739,"kind":"person","name":"Al-Marzooqi Fahed","position":1,"cik":"0001928247","reported_name":"Al-Marzooqi Fahed","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2026-06-29T20:09:07.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":35.08,"value":210480.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting."}],"balance_after":19555,"derivative":{"exercise_price":35.08,"expiration_date":"2036-06-26","underlying":"Class A Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001928247-26-000003","document":"wk-form4_1782763744.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000192824726000003/wk-form4_1782763744.xml","form_type":"4"}},{"id":723978,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2026-06-29T20:08:34.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":35.08,"value":210480.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting."}],"balance_after":16860,"derivative":{"exercise_price":35.08,"expiration_date":"2036-06-26","underlying":"Class A Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001627680-26-000006","document":"wk-form4_1782763711.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000162768026000006/wk-form4_1782763711.xml","form_type":"4"}},{"id":895707,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":65843,"kind":"person","name":"Tung Michael Stephen","position":1,"cik":"0002069755","reported_name":"Tung Michael Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Employee stock option (right to buy)","published_at":"2026-02-18T21:11:09.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":44969,"price":36.92,"value":1660255.48,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 25% on the first anniversary of the grant date and in quarterly equal installments thereafter."}],"balance_after":89969,"derivative":{"exercise_price":36.92,"expiration_date":"2036-02-17","underlying":"Class A Common Stock","underlying_shares":44969},"source":{"system":"sec-edgar","filing":"0002069755-26-000003","document":"wk-form4_1771449065.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000206975526000003/wk-form4_1771449065.xml","form_type":"4"}},{"id":896222,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":2147,"kind":"person","name":"SEKHRI PAUL J","position":1,"cik":"0001264519","reported_name":"SEKHRI PAUL J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres, CEO and Exec Chairperson"}}],"security":"Class A Common Stock","published_at":"2026-02-18T21:10:32.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":36.92,"value":5168800.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 25% on the first anniversary of the grant date and in quarterly equal installments thereafter."}],"balance_after":392212,"derivative":{"exercise_price":36.92,"expiration_date":"2036-02-17","underlying":"Class A Common Stock (\"Common Stock\")","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001264519-26-000002","document":"wk-form4_1771449023.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264519/000126451926000002/wk-form4_1771449023.xml","form_type":"4"}},{"id":1032167,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-09-25T21:04:22.000Z","date":"2025-09-22","kind":"grant","planned":false,"acquired":true,"shares":983214,"ownership":{"direct":false,"nature":"By Samsara Opportunity Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 29, 2025, Samsara Opportunity Fund, L.P. (\"Samsara Opportunity Fund\") entered into a securities purchase agreement with the Issuer pursuant to which Samsara Opportunity Fund purchased 106,000 shares of the Issuer's Class A Common Stock; pre-funded warrants exercisable for up to 877,214 shares of the Issuer's Class A Common Stock and common warrants exercisable for up to 983,214 shares of the Issuer's Class A Common Stock. The transaction closed on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 29, 2025, Samsara Opportunity Fund, L.P. (\"Samsara Opportunity Fund\") entered into a securities purchase agreement with the Issuer pursuant to which Samsara Opportunity Fund purchased 106,000 shares of the Issuer's Class A Common Stock; pre-funded warrants exercisable for up to 877,214 shares of the Issuer's Class A Common Stock and common warrants exercisable for up to 983,214 shares of the Issuer's Class A Common Stock. The transaction closed on September 22, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Common Warrants are immediately exercisable and expire on the earlier of (i) September 3, 2030 and (ii) the date that is 90 days after the date the Exercise Conditions (as defined in the Common Warrants) have been met.  A holder of Common Warrants may not exercise the Common Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Common Warrants are immediately exercisable and expire on the earlier of (i) September 3, 2030 and (ii) the date that is 90 days after the date the Exercise Conditions (as defined in the Common Warrants) have been met.  A holder of Common Warrants may not exercise the Common Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities are directly held by Samsara Opportunity Fund. Samsara Opportunity Fund GP, LLC (\"Samsara Opportunity GP\") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein."}],"balance_after":983214,"derivative":{"exercise_price":22.71,"underlying":"Class A Common Stock","underlying_shares":983214},"source":{"system":"sec-edgar","filing":"0001231919-25-000247","document":"form4-09252025_090918.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1253170/000123191925000247/form4-09252025_090918.xml","form_type":"4"}},{"id":1032166,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2025-09-25T21:04:22.000Z","date":"2025-09-22","kind":"grant","planned":false,"acquired":true,"shares":877214,"ownership":{"direct":false,"nature":"By Samsara Opportunity Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 29, 2025, Samsara Opportunity Fund, L.P. (\"Samsara Opportunity Fund\") entered into a securities purchase agreement with the Issuer pursuant to which Samsara Opportunity Fund purchased 106,000 shares of the Issuer's Class A Common Stock; pre-funded warrants exercisable for up to 877,214 shares of the Issuer's Class A Common Stock and common warrants exercisable for up to 983,214 shares of the Issuer's Class A Common Stock. The transaction closed on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 29, 2025, Samsara Opportunity Fund, L.P. (\"Samsara Opportunity Fund\") entered into a securities purchase agreement with the Issuer pursuant to which Samsara Opportunity Fund purchased 106,000 shares of the Issuer's Class A Common Stock; pre-funded warrants exercisable for up to 877,214 shares of the Issuer's Class A Common Stock and common warrants exercisable for up to 983,214 shares of the Issuer's Class A Common Stock. The transaction closed on September 22, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities are directly held by Samsara Opportunity Fund. Samsara Opportunity Fund GP, LLC (\"Samsara Opportunity GP\") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein."}],"balance_after":877214,"derivative":{"exercise_price":0.01,"underlying":"Class A Common Stock","underlying_shares":877214},"source":{"system":"sec-edgar","filing":"0001231919-25-000247","document":"form4-09252025_090918.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1253170/000123191925000247/form4-09252025_090918.xml","form_type":"4"}},{"id":1032165,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-09-25T21:04:22.000Z","date":"2025-09-22","kind":"grant","planned":false,"acquired":true,"shares":106000,"price":15.265,"value":1618090.0,"ownership":{"direct":false,"nature":"By Samsara Opportunity Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 29, 2025, Samsara Opportunity Fund, L.P. (\"Samsara Opportunity Fund\") entered into a securities purchase agreement with the Issuer pursuant to which Samsara Opportunity Fund purchased 106,000 shares of the Issuer's Class A Common Stock; pre-funded warrants exercisable for up to 877,214 shares of the Issuer's Class A Common Stock and common warrants exercisable for up to 983,214 shares of the Issuer's Class A Common Stock. The transaction closed on September 22, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities are directly held by Samsara Opportunity Fund. Samsara Opportunity Fund GP, LLC (\"Samsara Opportunity GP\") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein."}],"balance_after":106000,"source":{"system":"sec-edgar","filing":"0001231919-25-000247","document":"form4-09252025_090918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253170/000123191925000247/form4-09252025_090918.xml","form_type":"4"}},{"id":1046735,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to Purchase Class A Common Stock (Right to Buy)","published_at":"2025-09-05T22:10:28.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":655523,"ownership":{"direct":false,"nature":"By Samsara BioCapital, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 29, 2025, Samsara BioCapital, L.P. (\"Samsara LP\") entered into a securities purchase agreement with the Issuer pursuant to which Samsara LP purchased pre-funded warrants exercisable for up to 655,523 shares of the Issuer's Class A Common Stock and common warrants exercisable for up to 655,523 shares of the Issuer's Class A Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 29, 2025, Samsara BioCapital, L.P. (\"Samsara LP\") entered into a securities purchase agreement with the Issuer pursuant to which Samsara LP purchased pre-funded warrants exercisable for up to 655,523 shares of the Issuer's Class A Common Stock and common warrants exercisable for up to 655,523 shares of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Common Warrants are immediately exercisable and expire on the earlier of (i) September 3, 2030 and (ii) the date that is 90 days after the date the Exercise Conditions (as defined in the Common Warrants) have been met.  A holder of Common Warrants may not exercise the Common Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Common Warrants are immediately exercisable and expire on the earlier of (i) September 3, 2030 and (ii) the date that is 90 days after the date the Exercise Conditions (as defined in the Common Warrants) have been met.  A holder of Common Warrants may not exercise the Common Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by Samsara LP. Samsara BioCapital GP, LLC (\"Samsara LLC\") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein."}],"balance_after":655523,"derivative":{"exercise_price":22.71,"underlying":"Class A Common Stock","underlying_shares":655523},"source":{"system":"sec-edgar","filing":"0001415889-25-023816","document":"form4-09052025_100925.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253170/000141588925023816/form4-09052025_100925.xml","form_type":"4"}},{"id":1046734,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2025-09-05T22:10:28.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":655523,"ownership":{"direct":false,"nature":"Samsara BioCapital, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 29, 2025, Samsara BioCapital, L.P. (\"Samsara LP\") entered into a securities purchase agreement with the Issuer pursuant to which Samsara LP purchased pre-funded warrants exercisable for up to 655,523 shares of the Issuer's Class A Common Stock and common warrants exercisable for up to 655,523 shares of the Issuer's Class A Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 29, 2025, Samsara BioCapital, L.P. (\"Samsara LP\") entered into a securities purchase agreement with the Issuer pursuant to which Samsara LP purchased pre-funded warrants exercisable for up to 655,523 shares of the Issuer's Class A Common Stock and common warrants exercisable for up to 655,523 shares of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by Samsara LP. Samsara BioCapital GP, LLC (\"Samsara LLC\") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein."}],"balance_after":1548101,"derivative":{"exercise_price":0.01,"underlying":"Class A Common Stock","underlying_shares":655523},"source":{"system":"sec-edgar","filing":"0001415889-25-023816","document":"form4-09052025_100925.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253170/000141588925023816/form4-09052025_100925.xml","form_type":"4"}},{"id":1047091,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrant","published_at":"2025-09-05T20:15:03.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":2400605,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Pursuant to a securities purchase agreement (the \"SPA\") entered into between vTv Therapeutics Inc. (the \"Issuer\") and 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") and other institutional investors, the Issuer agreed to issue and sell and 667 and Life Sciences agreed to acquire in a private placement (\"Private Placement\") that closed on September 3, 2025 221,452 and 2,400,605 units (the \"Units\"), respectively, each Unit comprised of (i) (A) one share of the Issuer's Class A Common Stock (\"Common Stock\") or (B) a prefunded warrant to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\") and (ii) a warrant (the \"Common Warrants\") to purchase, at the holder's election, either one share of Common Stock or a Prefunded Warrant."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The Common Warrants are exercisable for (x) $22.71, if exercised for a shares of Common Stock, or (y) $22.70, if exercised for a Prefunded Warrant, in either case, at any time after their original issuance, and will expire upon the earlier to occur of (i) September 3, 2030 and (ii) 90 days following the announcement of positive top-line data from the Issuer's ongoing CATT1 clinical trial."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to a securities purchase agreement (the \"SPA\") entered into between vTv Therapeutics Inc. (the \"Issuer\") and 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") and other institutional investors, the Issuer agreed to issue and sell and 667 and Life Sciences agreed to acquire in a private placement (\"Private Placement\") that closed on September 3, 2025 221,452 and 2,400,605 units (the \"Units\"), respectively, each Unit comprised of (i) (A) one share of the Issuer's Class A Common Stock (\"Common Stock\") or (B) a prefunded warrant to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\") and (ii) a warrant (the \"Common Warrants\") to purchase, at the holder's election, either one share of Common Stock or a Prefunded Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a securities purchase agreement (the \"SPA\") entered into between vTv Therapeutics Inc. (the \"Issuer\") and 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") and other institutional investors, the Issuer agreed to issue and sell and 667 and Life Sciences agreed to acquire in a private placement (\"Private Placement\") that closed on September 3, 2025 221,452 and 2,400,605 units (the \"Units\"), respectively, each Unit comprised of (i) (A) one share of the Issuer's Class A Common Stock (\"Common Stock\") or (B) a prefunded warrant to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\") and (ii) a warrant (the \"Common Warrants\") to purchase, at the holder's election, either one share of Common Stock or a Prefunded Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Units were sold at a per-Unit price of (x) $15.265, in the case of Units including a share of Common Stock, and (y) $15.255, in the case of Units including a Prefunded Warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Prefunded Warrants and Common Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"By written notice to the Issuer, 667 and Life Sciences may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The Common Warrants are exercisable for (x) $22.71, if exercised for a shares of Common Stock, or (y) $22.70, if exercised for a Prefunded Warrant, in either case, at any time after their original issuance, and will expire upon the earlier to occur of (i) September 3, 2030 and (ii) 90 days following the announcement of positive top-line data from the Issuer's ongoing CATT1 clinical trial."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Common Warrants are exercisable for (x) $22.71, if exercised for a shares of Common Stock, or (y) $22.70, if exercised for a Prefunded Warrant, in either case, at any time after their original issuance, and will expire upon the earlier to occur of (i) September 3, 2030 and (ii) 90 days following the announcement of positive top-line data from the Issuer's ongoing CATT1 clinical trial."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F9","text":"The Common Warrants are exercisable for (x) $22.71, if exercised for a shares of Common Stock, or (y) $22.70, if exercised for a Prefunded Warrant, in either case, at any time after their original issuance, and will expire upon the earlier to occur of (i) September 3, 2030 and (ii) 90 days following the announcement of positive top-line data from the Issuer's ongoing CATT1 clinical trial."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I or securities reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":2400605,"derivative":{"underlying":"Common Stock or Prefunded Warrant","underlying_shares":2400605},"source":{"system":"sec-edgar","filing":"0000950170-25-113252","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017025113252/ownership.xml","form_type":"4"}},{"id":1047090,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrant","published_at":"2025-09-05T20:15:03.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":221452,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Pursuant to a securities purchase agreement (the \"SPA\") entered into between vTv Therapeutics Inc. (the \"Issuer\") and 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") and other institutional investors, the Issuer agreed to issue and sell and 667 and Life Sciences agreed to acquire in a private placement (\"Private Placement\") that closed on September 3, 2025 221,452 and 2,400,605 units (the \"Units\"), respectively, each Unit comprised of (i) (A) one share of the Issuer's Class A Common Stock (\"Common Stock\") or (B) a prefunded warrant to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\") and (ii) a warrant (the \"Common Warrants\") to purchase, at the holder's election, either one share of Common Stock or a Prefunded Warrant."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The Common Warrants are exercisable for (x) $22.71, if exercised for a shares of Common Stock, or (y) $22.70, if exercised for a Prefunded Warrant, in either case, at any time after their original issuance, and will expire upon the earlier to occur of (i) September 3, 2030 and (ii) 90 days following the announcement of positive top-line data from the Issuer's ongoing CATT1 clinical trial."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to a securities purchase agreement (the \"SPA\") entered into between vTv Therapeutics Inc. (the \"Issuer\") and 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") and other institutional investors, the Issuer agreed to issue and sell and 667 and Life Sciences agreed to acquire in a private placement (\"Private Placement\") that closed on September 3, 2025 221,452 and 2,400,605 units (the \"Units\"), respectively, each Unit comprised of (i) (A) one share of the Issuer's Class A Common Stock (\"Common Stock\") or (B) a prefunded warrant to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\") and (ii) a warrant (the \"Common Warrants\") to purchase, at the holder's election, either one share of Common Stock or a Prefunded Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a securities purchase agreement (the \"SPA\") entered into between vTv Therapeutics Inc. (the \"Issuer\") and 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") and other institutional investors, the Issuer agreed to issue and sell and 667 and Life Sciences agreed to acquire in a private placement (\"Private Placement\") that closed on September 3, 2025 221,452 and 2,400,605 units (the \"Units\"), respectively, each Unit comprised of (i) (A) one share of the Issuer's Class A Common Stock (\"Common Stock\") or (B) a prefunded warrant to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\") and (ii) a warrant (the \"Common Warrants\") to purchase, at the holder's election, either one share of Common Stock or a Prefunded Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Units were sold at a per-Unit price of (x) $15.265, in the case of Units including a share of Common Stock, and (y) $15.255, in the case of Units including a Prefunded Warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Prefunded Warrants and Common Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"By written notice to the Issuer, 667 and Life Sciences may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The Common Warrants are exercisable for (x) $22.71, if exercised for a shares of Common Stock, or (y) $22.70, if exercised for a Prefunded Warrant, in either case, at any time after their original issuance, and will expire upon the earlier to occur of (i) September 3, 2030 and (ii) 90 days following the announcement of positive top-line data from the Issuer's ongoing CATT1 clinical trial."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Common Warrants are exercisable for (x) $22.71, if exercised for a shares of Common Stock, or (y) $22.70, if exercised for a Prefunded Warrant, in either case, at any time after their original issuance, and will expire upon the earlier to occur of (i) September 3, 2030 and (ii) 90 days following the announcement of positive top-line data from the Issuer's ongoing CATT1 clinical trial."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F9","text":"The Common Warrants are exercisable for (x) $22.71, if exercised for a shares of Common Stock, or (y) $22.70, if exercised for a Prefunded Warrant, in either case, at any time after their original issuance, and will expire upon the earlier to occur of (i) September 3, 2030 and (ii) 90 days following the announcement of positive top-line data from the Issuer's ongoing CATT1 clinical trial."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I or securities reported in column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":221452,"derivative":{"underlying":"Common Stock or Prefunded Warrant","underlying_shares":221452},"source":{"system":"sec-edgar","filing":"0000950170-25-113252","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017025113252/ownership.xml","form_type":"4"}},{"id":1047089,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Prefunded Warrants","published_at":"2025-09-05T20:15:03.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":2353913,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Pursuant to a securities purchase agreement (the \"SPA\") entered into between vTv Therapeutics Inc. (the \"Issuer\") and 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") and other institutional investors, the Issuer agreed to issue and sell and 667 and Life Sciences agreed to acquire in a private placement (\"Private Placement\") that closed on September 3, 2025 221,452 and 2,400,605 units (the \"Units\"), respectively, each Unit comprised of (i) (A) one share of the Issuer's Class A Common Stock (\"Common Stock\") or (B) a prefunded warrant to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\") and (ii) a warrant (the \"Common Warrants\") to purchase, at the holder's election, either one share of Common Stock or a Prefunded Warrant."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to a securities purchase agreement (the \"SPA\") entered into between vTv Therapeutics Inc. (the \"Issuer\") and 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") and other institutional investors, the Issuer agreed to issue and sell and 667 and Life Sciences agreed to acquire in a private placement (\"Private Placement\") that closed on September 3, 2025 221,452 and 2,400,605 units (the \"Units\"), respectively, each Unit comprised of (i) (A) one share of the Issuer's Class A Common Stock (\"Common Stock\") or (B) a prefunded warrant to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\") and (ii) a warrant (the \"Common Warrants\") to purchase, at the holder's election, either one share of Common Stock or a Prefunded Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a securities purchase agreement (the \"SPA\") entered into between vTv Therapeutics Inc. (the \"Issuer\") and 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") and other institutional investors, the Issuer agreed to issue and sell and 667 and Life Sciences agreed to acquire in a private placement (\"Private Placement\") that closed on September 3, 2025 221,452 and 2,400,605 units (the \"Units\"), respectively, each Unit comprised of (i) (A) one share of the Issuer's Class A Common Stock (\"Common Stock\") or (B) a prefunded warrant to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\") and (ii) a warrant (the \"Common Warrants\") to purchase, at the holder's election, either one share of Common Stock or a Prefunded Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Units were sold at a per-Unit price of (x) $15.265, in the case of Units including a share of Common Stock, and (y) $15.255, in the case of Units including a Prefunded Warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Prefunded Warrants and Common Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"By written notice to the Issuer, 667 and Life Sciences may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to a securities purchase agreement (the \"SPA\") entered into between vTv Therapeutics Inc. (the \"Issuer\") and 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") and other institutional investors, the Issuer agreed to issue and sell and 667 and Life Sciences agreed to acquire in a private placement (\"Private Placement\") that closed on September 3, 2025 221,452 and 2,400,605 units (the \"Units\"), respectively, each Unit comprised of (i) (A) one share of the Issuer's Class A Common Stock (\"Common Stock\") or (B) a prefunded warrant to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\") and (ii) a warrant (the \"Common Warrants\") to purchase, at the holder's election, either one share of Common Stock or a Prefunded Warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I or securities reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":5176974,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":2353913},"source":{"system":"sec-edgar","filing":"0000950170-25-113252","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017025113252/ownership.xml","form_type":"4"}},{"id":1047088,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Prefunded Warrants","published_at":"2025-09-05T20:15:03.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":217144,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Pursuant to a securities purchase agreement (the \"SPA\") entered into between vTv Therapeutics Inc. (the \"Issuer\") and 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") and other institutional investors, the Issuer agreed to issue and sell and 667 and Life Sciences agreed to acquire in a private placement (\"Private Placement\") that closed on September 3, 2025 221,452 and 2,400,605 units (the \"Units\"), respectively, each Unit comprised of (i) (A) one share of the Issuer's Class A Common Stock (\"Common Stock\") or (B) a prefunded warrant to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\") and (ii) a warrant (the \"Common Warrants\") to purchase, at the holder's election, either one share of Common Stock or a Prefunded Warrant."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to a securities purchase agreement (the \"SPA\") entered into between vTv Therapeutics Inc. (the \"Issuer\") and 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") and other institutional investors, the Issuer agreed to issue and sell and 667 and Life Sciences agreed to acquire in a private placement (\"Private Placement\") that closed on September 3, 2025 221,452 and 2,400,605 units (the \"Units\"), respectively, each Unit comprised of (i) (A) one share of the Issuer's Class A Common Stock (\"Common Stock\") or (B) a prefunded warrant to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\") and (ii) a warrant (the \"Common Warrants\") to purchase, at the holder's election, either one share of Common Stock or a Prefunded Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a securities purchase agreement (the \"SPA\") entered into between vTv Therapeutics Inc. (the \"Issuer\") and 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") and other institutional investors, the Issuer agreed to issue and sell and 667 and Life Sciences agreed to acquire in a private placement (\"Private Placement\") that closed on September 3, 2025 221,452 and 2,400,605 units (the \"Units\"), respectively, each Unit comprised of (i) (A) one share of the Issuer's Class A Common Stock (\"Common Stock\") or (B) a prefunded warrant to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\") and (ii) a warrant (the \"Common Warrants\") to purchase, at the holder's election, either one share of Common Stock or a Prefunded Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Units were sold at a per-Unit price of (x) $15.265, in the case of Units including a share of Common Stock, and (y) $15.255, in the case of Units including a Prefunded Warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Prefunded Warrants and Common Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"By written notice to the Issuer, 667 and Life Sciences may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to a securities purchase agreement (the \"SPA\") entered into between vTv Therapeutics Inc. (the \"Issuer\") and 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") and other institutional investors, the Issuer agreed to issue and sell and 667 and Life Sciences agreed to acquire in a private placement (\"Private Placement\") that closed on September 3, 2025 221,452 and 2,400,605 units (the \"Units\"), respectively, each Unit comprised of (i) (A) one share of the Issuer's Class A Common Stock (\"Common Stock\") or (B) a prefunded warrant to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\") and (ii) a warrant (the \"Common Warrants\") to purchase, at the holder's election, either one share of Common Stock or a Prefunded Warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I or securities reported in column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":472092,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":217144},"source":{"system":"sec-edgar","filing":"0000950170-25-113252","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017025113252/ownership.xml","form_type":"4"}},{"id":1047087,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-05T20:15:03.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":46692,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to a securities purchase agreement (the \"SPA\") entered into between vTv Therapeutics Inc. (the \"Issuer\") and 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") and other institutional investors, the Issuer agreed to issue and sell and 667 and Life Sciences agreed to acquire in a private placement (\"Private Placement\") that closed on September 3, 2025 221,452 and 2,400,605 units (the \"Units\"), respectively, each Unit comprised of (i) (A) one share of the Issuer's Class A Common Stock (\"Common Stock\") or (B) a prefunded warrant to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\") and (ii) a warrant (the \"Common Warrants\") to purchase, at the holder's election, either one share of Common Stock or a Prefunded Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a securities purchase agreement (the \"SPA\") entered into between vTv Therapeutics Inc. (the \"Issuer\") and 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") and other institutional investors, the Issuer agreed to issue and sell and 667 and Life Sciences agreed to acquire in a private placement (\"Private Placement\") that closed on September 3, 2025 221,452 and 2,400,605 units (the \"Units\"), respectively, each Unit comprised of (i) (A) one share of the Issuer's Class A Common Stock (\"Common Stock\") or (B) a prefunded warrant to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\") and (ii) a warrant (the \"Common Warrants\") to purchase, at the holder's election, either one share of Common Stock or a Prefunded Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Units were sold at a per-Unit price of (x) $15.265, in the case of Units including a share of Common Stock, and (y) $15.255, in the case of Units including a Prefunded Warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I or securities reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":135946,"source":{"system":"sec-edgar","filing":"0000950170-25-113252","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017025113252/ownership.xml","form_type":"4"}},{"id":1047086,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-05T20:15:03.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":4308,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to a securities purchase agreement (the \"SPA\") entered into between vTv Therapeutics Inc. (the \"Issuer\") and 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") and other institutional investors, the Issuer agreed to issue and sell and 667 and Life Sciences agreed to acquire in a private placement (\"Private Placement\") that closed on September 3, 2025 221,452 and 2,400,605 units (the \"Units\"), respectively, each Unit comprised of (i) (A) one share of the Issuer's Class A Common Stock (\"Common Stock\") or (B) a prefunded warrant to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\") and (ii) a warrant (the \"Common Warrants\") to purchase, at the holder's election, either one share of Common Stock or a Prefunded Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a securities purchase agreement (the \"SPA\") entered into between vTv Therapeutics Inc. (the \"Issuer\") and 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") and other institutional investors, the Issuer agreed to issue and sell and 667 and Life Sciences agreed to acquire in a private placement (\"Private Placement\") that closed on September 3, 2025 221,452 and 2,400,605 units (the \"Units\"), respectively, each Unit comprised of (i) (A) one share of the Issuer's Class A Common Stock (\"Common Stock\") or (B) a prefunded warrant to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\") and (ii) a warrant (the \"Common Warrants\") to purchase, at the holder's election, either one share of Common Stock or a Prefunded Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Units were sold at a per-Unit price of (x) $15.265, in the case of Units including a share of Common Stock, and (y) $15.255, in the case of Units including a Prefunded Warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I or securities reported in column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":12368,"source":{"system":"sec-edgar","filing":"0000950170-25-113252","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017025113252/ownership.xml","form_type":"4"}},{"id":1114075,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non- Qualified Stock Option (right to buy)","published_at":"2025-06-12T20:28:34.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 4,000 non-qualified stock options (\"Stock Options\") exercisable solely into Class A common stock (\"Common Stock\") of vTv Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 10, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2024 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $16.59 per share and vest on the earlier of June 10, 2026 or the date of the 2026 annual general meeting of the Issuer's shareholders, subject to Dr. Cheong's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 10, 2035."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 4,000 non-qualified stock options (\"Stock Options\") exercisable solely into Class A common stock (\"Common Stock\") of vTv Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 10, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2024 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $16.59 per share and vest on the earlier of June 10, 2026 or the date of the 2026 annual general meeting of the Issuer's shareholders, subject to Dr. Cheong's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 10, 2035."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Cheong serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Dr. Cheong does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents a single grant to Dr. Cheong of 4,000 Stock Options on Table II. This grant of 4,000 Stock Options for Dr. Cheong is reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":4000,"derivative":{"exercise_price":16.59,"expiration_date":"2035-06-10","underlying":"Class A common stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0000950170-25-085453","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017025085453/ownership.xml","form_type":"4"}},{"id":1114074,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non- Qualified Stock Option (right to buy)","published_at":"2025-06-12T20:28:34.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 4,000 non-qualified stock options (\"Stock Options\") exercisable solely into Class A common stock (\"Common Stock\") of vTv Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 10, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2024 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $16.59 per share and vest on the earlier of June 10, 2026 or the date of the 2026 annual general meeting of the Issuer's shareholders, subject to Dr. Cheong's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 10, 2035."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 4,000 non-qualified stock options (\"Stock Options\") exercisable solely into Class A common stock (\"Common Stock\") of vTv Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 10, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2024 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $16.59 per share and vest on the earlier of June 10, 2026 or the date of the 2026 annual general meeting of the Issuer's shareholders, subject to Dr. Cheong's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 10, 2035."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Cheong serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Dr. Cheong does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents a single grant to Dr. Cheong of 4,000 Stock Options on Table II. This grant of 4,000 Stock Options for Dr. Cheong is reported for each of the Funds as each has an indirect pecuniary interest in such securities."}],"balance_after":4000,"derivative":{"exercise_price":16.59,"expiration_date":"2035-06-10","underlying":"Class A common stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0000950170-25-085453","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017025085453/ownership.xml","form_type":"4"}},{"id":1113100,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2025-06-12T20:28:17.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":16.59,"value":66360.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of June 10, 2026, and the date of the 2026 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting."}],"balance_after":10000,"derivative":{"exercise_price":16.59,"expiration_date":"2035-06-10","underlying":"Class A Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001641489-25-000046","document":"wk-form4_1749760089.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1238403/000164148925000046/wk-form4_1749760089.xml","form_type":"4"}},{"id":1113043,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2025-06-12T20:27:28.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":16.59,"value":66360.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of June 10, 2026, and the date of the 2026 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting."}],"balance_after":10983,"derivative":{"exercise_price":16.59,"expiration_date":"2035-06-10","underlying":"Class A Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001641489-25-000044","document":"wk-form4_1749760036.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253170/000164148925000044/wk-form4_1749760036.xml","form_type":"4"}},{"id":1113306,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2025-06-12T20:26:08.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":16.59,"value":66360.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of June 10, 2026, and the date of the 2026 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting."}],"balance_after":10860,"derivative":{"exercise_price":16.59,"expiration_date":"2035-06-10","underlying":"Class A Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001641489-25-000042","document":"wk-form4_1749759962.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000164148925000042/wk-form4_1749759962.xml","form_type":"4"}},{"id":1112867,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34739,"kind":"person","name":"Al-Marzooqi Fahed","position":1,"cik":"0001928247","reported_name":"Al-Marzooqi Fahed","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2025-06-12T20:25:07.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":16.59,"value":66360.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of June 10, 2026, and the date of the 2026 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting."}],"balance_after":13555,"derivative":{"exercise_price":16.59,"expiration_date":"2035-06-10","underlying":"Class A Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001641489-25-000040","document":"wk-form4_1749759899.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148925000040/wk-form4_1749759899.xml","form_type":"4"}},{"id":1138617,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":65843,"kind":"person","name":"Tung Michael Stephen","position":1,"cik":"0002069755","reported_name":"Tung Michael Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Employee stock option (right to buy)","published_at":"2025-05-21T22:17:21.000Z","date":"2025-05-19","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":21.25,"value":956250.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests 25% on the 1st anniversary of the grant and the remaining vest quarterly over three years, subject to continued employment."}],"balance_after":45000,"derivative":{"exercise_price":21.25,"expiration_date":"2035-05-19","underlying":"Class A Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001641489-25-000036","document":"wk-form4_1747865835.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148925000036/wk-form4_1747865835.xml","form_type":"4"}},{"id":1166270,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2025-04-24T20:40:29.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":983,"price":17.22,"value":16927.26,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in full on the one-year anniversary of the date of grant"}],"balance_after":6983,"derivative":{"exercise_price":17.22,"exercise_date":"2025-06-25","expiration_date":"2034-06-25","underlying":"Class A Common Stock","underlying_shares":983},"source":{"system":"sec-edgar","filing":"0001641489-25-000022","document":"wk-form4_1745527221.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253170/000164148925000022/wk-form4_1745527221.xml","form_type":"4"}},{"id":1166269,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2025-04-24T20:40:29.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":2250,"price":17.22,"value":38745.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest monthly over the three year period following the date of grant."}],"balance_after":6000,"derivative":{"exercise_price":17.22,"expiration_date":"2034-06-25","underlying":"Class A Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001641489-25-000022","document":"wk-form4_1745527221.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253170/000164148925000022/wk-form4_1745527221.xml","form_type":"4"}},{"id":1217118,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":2147,"kind":"person","name":"SEKHRI PAUL J","position":1,"cik":"0001264519","reported_name":"SEKHRI PAUL J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres, CEO and Exec Chairperson"}}],"security":"Employee stock option (right to buy)","published_at":"2025-03-07T21:20:26.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":108000,"price":19.66,"value":2123280.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 25% on the first anniversary of the grant date and in quarterly equal installments thereafter."}],"balance_after":252212,"derivative":{"exercise_price":19.66,"expiration_date":"2035-03-01","underlying":"Class A Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001641489-25-000007","document":"wk-form4_1741382420.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264519/000164148925000007/wk-form4_1741382420.xml","form_type":"4"}},{"id":1340102,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":44747,"kind":"organization","name":"Samsara BioCapital GP, LLC","position":1,"cik":"0001888829","reported_name":"Samsara BioCapital GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44746,"kind":"organization","name":"Samsara BioCapital, L.P.","position":2,"cik":"0001699737","reported_name":"Samsara BioCapital, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre- Funded Warrants (Right to Buy)","published_at":"2024-12-06T21:15:18.000Z","date":"2024-03-05","kind":"grant","planned":false,"acquired":true,"shares":58885,"ownership":{"direct":false,"nature":"Samsara BioCapital, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 5, 2024, Samsara BioCapital, L.P. (\"Samsara LP\") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants\nexercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 5, 2024, Samsara BioCapital, L.P. (\"Samsara LP\") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants\nexercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by Samsara LP. Samsara BioCapital GP, LLC (\"Samsara LLC\") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership in these securities except to the extent of its pecuniary interest therein. Dr. Akkaraju is a director of the Issuer and files separate Section 16 reports."}],"balance_after":892578,"derivative":{"exercise_price":0.01,"underlying":"Class A Common Stock","underlying_shares":58885},"source":{"system":"sec-edgar","filing":"0001415889-24-028465","document":"form4-12062024_041204.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000141588924028465/form4-12062024_041204.xml","form_type":"4"}},{"id":1340101,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":44747,"kind":"organization","name":"Samsara BioCapital GP, LLC","position":1,"cik":"0001888829","reported_name":"Samsara BioCapital GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44746,"kind":"organization","name":"Samsara BioCapital, L.P.","position":2,"cik":"0001699737","reported_name":"Samsara BioCapital, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2024-12-06T21:15:18.000Z","date":"2024-03-05","kind":"other","planned":false,"acquired":false,"shares":58836,"ownership":{"direct":false,"nature":"By Samsara BioCapital, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 5, 2024, Samsara BioCapital, L.P. (\"Samsara LP\") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants\nexercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 5, 2024, Samsara BioCapital, L.P. (\"Samsara LP\") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants\nexercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by Samsara LP. Samsara BioCapital GP, LLC (\"Samsara LLC\") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership in these securities except to the extent of its pecuniary interest therein. Dr. Akkaraju is a director of the Issuer and files separate Section 16 reports."}],"balance_after":206784,"source":{"system":"sec-edgar","filing":"0001415889-24-028465","document":"form4-12062024_041204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000141588924028465/form4-12062024_041204.xml","form_type":"4"}},{"id":1340239,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre- Funded Warrants (Right to Buy)","published_at":"2024-12-06T21:15:16.000Z","date":"2024-03-05","kind":"grant","planned":false,"acquired":true,"shares":58885,"ownership":{"direct":false,"nature":"Samsara BioCapital, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 5, 2024, Samsara BioCapital, L.P. (\"Samsara LP\") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants\nexercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 5, 2024, Samsara BioCapital, L.P. (\"Samsara LP\") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants\nexercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by Samsara LP. Samsara BioCapital GP, LLC (\"Samsara LLC\") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein."}],"balance_after":892578,"derivative":{"exercise_price":0.01,"underlying":"Class A Common Stock","underlying_shares":58885},"source":{"system":"sec-edgar","filing":"0001415889-24-028464","document":"form4-12062024_041202.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253170/000141588924028464/form4-12062024_041202.xml","form_type":"4"}},{"id":1340238,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2024-12-06T21:15:16.000Z","date":"2024-03-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":58836,"ownership":{"direct":false,"nature":"By Samsara BioCapital, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 5, 2024, Samsara BioCapital, L.P. (\"Samsara LP\") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants\nexercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 5, 2024, Samsara BioCapital, L.P. (\"Samsara LP\") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants\nexercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by Samsara LP. Samsara BioCapital GP, LLC (\"Samsara LLC\") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein."}],"balance_after":206784,"source":{"system":"sec-edgar","filing":"0001415889-24-028464","document":"form4-12062024_041202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253170/000141588924028464/form4-12062024_041202.xml","form_type":"4"}},{"id":1358793,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":2147,"kind":"person","name":"SEKHRI PAUL J","position":1,"cik":"0001264519","reported_name":"SEKHRI PAUL J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres, CEO and Exec Chairperson"}}],"security":"Class A Common Stock","published_at":"2024-11-19T21:31:06.000Z","date":"2024-11-18","kind":"purchase","planned":true,"acquired":true,"shares":1844,"price":16.9569,"value":31268.5236,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Sekhri on August 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average purchase price.  These shares were purchased in multiple transactions at prices ranging from $16.70 to $17.00.  The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001641489-24-000078","document":"wk-form4_1732051858.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1264519/000164148924000078/wk-form4_1732051858.xml","form_type":"4"}},{"id":1358792,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":2147,"kind":"person","name":"SEKHRI PAUL J","position":1,"cik":"0001264519","reported_name":"SEKHRI PAUL J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres, CEO and Exec Chairperson"}}],"security":"Class A Common Stock","published_at":"2024-11-19T21:31:06.000Z","date":"2024-11-15","kind":"purchase","planned":true,"acquired":true,"shares":1778,"price":16.8781,"value":30009.2618,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Sekhri on August 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average purchase price.  These shares were purchased in multiple transactions at prices ranging from $16.71 to $17.00.  The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":3156,"source":{"system":"sec-edgar","filing":"0001641489-24-000078","document":"wk-form4_1732051858.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264519/000164148924000078/wk-form4_1732051858.xml","form_type":"4"}},{"id":1358791,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":2147,"kind":"person","name":"SEKHRI PAUL J","position":1,"cik":"0001264519","reported_name":"SEKHRI PAUL J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres, CEO and Exec Chairperson"}}],"security":"Class A Common Stock","published_at":"2024-11-19T21:31:06.000Z","date":"2024-11-15","kind":"purchase","planned":true,"acquired":true,"shares":1378,"price":16.3528,"value":22534.1584,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Sekhri on August 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average purchase price.  These shares were purchased in multiple transactions at prices ranging from $15.65 to $16.50.  The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":1378,"source":{"system":"sec-edgar","filing":"0001641489-24-000078","document":"wk-form4_1732051858.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264519/000164148924000078/wk-form4_1732051858.xml","form_type":"4"}},{"id":1468371,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non- Qualified Stock Option (right to buy)","published_at":"2024-06-27T21:39:07.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":983,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F10","text":"Includes 983 Stock Options granted by the Issuer to Dr. Cheong in his capacity as a director of the Issuer, pursuant to the Incentive Plan. The Stock Options have a strike price of $17.22 per share and vest on the first anniversary of the grant date, subject to Dr. Cheong's continued service on the Board through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 25, 2034."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Includes 983 Stock Options granted by the Issuer to Dr. Cheong in his capacity as a director of the Issuer, pursuant to the Incentive Plan. The Stock Options have a strike price of $17.22 per share and vest on the first anniversary of the grant date, subject to Dr. Cheong's continued service on the Board through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 25, 2034."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Cheong serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Dr. Cheong does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents two grants to Dr. Cheong for 6,000 Stock Options and 983 Stock Options on Table II. These two grants for 6,000 Stock Options and 983 Stock Options for Dr. Cheong are reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":983,"derivative":{"exercise_price":17.22,"expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":983},"source":{"system":"sec-edgar","filing":"0000950170-24-078626","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017024078626/ownership.xml","form_type":"4"}},{"id":1468370,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non- Qualified Stock Option (right to buy)","published_at":"2024-06-27T21:39:07.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":983,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F10","text":"Includes 983 Stock Options granted by the Issuer to Dr. Cheong in his capacity as a director of the Issuer, pursuant to the Incentive Plan. The Stock Options have a strike price of $17.22 per share and vest on the first anniversary of the grant date, subject to Dr. Cheong's continued service on the Board through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 25, 2034."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Includes 983 Stock Options granted by the Issuer to Dr. Cheong in his capacity as a director of the Issuer, pursuant to the Incentive Plan. The Stock Options have a strike price of $17.22 per share and vest on the first anniversary of the grant date, subject to Dr. Cheong's continued service on the Board through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 25, 2034."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Cheong serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Dr. Cheong does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents two grants to Dr. Cheong for 6,000 Stock Options and 983 Stock Options on Table II. These two grants for 6,000 Stock Options and 983 Stock Options for Dr. Cheong are reported for each of the Funds as each has an indirect pecuniary interest in such securities."}],"balance_after":983,"derivative":{"exercise_price":17.22,"expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":983},"source":{"system":"sec-edgar","filing":"0000950170-24-078626","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017024078626/ownership.xml","form_type":"4"}},{"id":1468369,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non- Qualified Stock Option (right to buy)","published_at":"2024-06-27T21:39:07.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 6,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of vTv Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 25, 2024, in his capacity as a director of the Issuer, pursuant to the Issuer's 2024 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $17.22 per share and vest in equal monthly installments over three years, subject to Dr. Cheong's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 25, 2034."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 6,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of vTv Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 25, 2024, in his capacity as a director of the Issuer, pursuant to the Issuer's 2024 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $17.22 per share and vest in equal monthly installments over three years, subject to Dr. Cheong's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 25, 2034."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Cheong serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Dr. Cheong does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents two grants to Dr. Cheong for 6,000 Stock Options and 983 Stock Options on Table II. These two grants for 6,000 Stock Options and 983 Stock Options for Dr. Cheong are reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":6000,"derivative":{"exercise_price":17.22,"expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000950170-24-078626","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017024078626/ownership.xml","form_type":"4"}},{"id":1468368,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non- Qualified Stock Option (right to buy)","published_at":"2024-06-27T21:39:07.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 6,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of vTv Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 25, 2024, in his capacity as a director of the Issuer, pursuant to the Issuer's 2024 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $17.22 per share and vest in equal monthly installments over three years, subject to Dr. Cheong's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 25, 2034."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 6,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of vTv Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 25, 2024, in his capacity as a director of the Issuer, pursuant to the Issuer's 2024 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $17.22 per share and vest in equal monthly installments over three years, subject to Dr. Cheong's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 25, 2034."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Cheong serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Dr. Cheong does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents two grants to Dr. Cheong for 6,000 Stock Options and 983 Stock Options on Table II. These two grants for 6,000 Stock Options and 983 Stock Options for Dr. Cheong are reported for each of the Funds as each has an indirect pecuniary interest in such securities."}],"balance_after":6000,"derivative":{"exercise_price":17.22,"expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000950170-24-078626","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017024078626/ownership.xml","form_type":"4"}},{"id":1468028,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2024-06-27T20:40:22.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":17.22,"value":103320.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest monthly over the three year period following date of grant."}],"balance_after":6000,"derivative":{"exercise_price":17.22,"expiration_date":"2034-06-25","underlying":"Class A Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001641489-24-000051","document":"wk-form4_1719520815.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1238403/000164148924000051/wk-form4_1719520815.xml","form_type":"4"}},{"id":1467940,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34739,"kind":"person","name":"Al-Marzooqi Fahed","position":1,"cik":"0001928247","reported_name":"Al-Marzooqi Fahed","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2024-06-27T20:38:49.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":17.22,"value":51660.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest on the one-year anniversary of the date of grant"}],"balance_after":9555,"derivative":{"exercise_price":17.22,"exercise_date":"2025-06-25","expiration_date":"2034-06-25","underlying":"Class A Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001641489-24-000049","document":"wk-form4_1719520722.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000049/wk-form4_1719520722.xml","form_type":"4"}},{"id":1468110,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2024-06-27T20:37:18.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":860,"price":17.22,"value":14809.2,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in full on the one-year anniversary of the date of grant"}],"balance_after":6860,"derivative":{"exercise_price":17.22,"exercise_date":"2025-06-25","expiration_date":"2034-06-25","underlying":"Class A Common Stock","underlying_shares":860},"source":{"system":"sec-edgar","filing":"0001641489-24-000047","document":"wk-form4_1719520629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000164148924000047/wk-form4_1719520629.xml","form_type":"4"}},{"id":1468109,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2024-06-27T20:37:18.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":2250,"price":17.22,"value":38745.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest monthly over the three year period following the date of grant."}],"balance_after":6000,"derivative":{"exercise_price":17.22,"expiration_date":"2034-06-25","underlying":"Class A Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001641489-24-000047","document":"wk-form4_1719520629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000164148924000047/wk-form4_1719520629.xml","form_type":"4"}},{"id":1480341,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-13T22:22:53.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a three-year period commencing on the one-month anniversary of February 27, 2024, subject to the Reporting Person's continuous service as of each applicable vesting date."}],"balance_after":3750,"derivative":{"exercise_price":8.5,"expiration_date":"2034-02-27","underlying":"Class A Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001415889-24-016730","document":"form4-06132024_100649.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253170/000141588924016730/form4-06132024_100649.xml","form_type":"4"}},{"id":1480183,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34739,"kind":"person","name":"Al-Marzooqi Fahed","position":1,"cik":"0001928247","reported_name":"Al-Marzooqi Fahed","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2024-06-13T20:42:02.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":4055,"price":11.81,"value":47889.55,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in quarterly equal installments over the three year period beginning on February 27, 2024.  The option was conditioned upon shareholder approval of the 2024 Equity Incentive Plan, which was approved by the shareholders on June 11, 2024."}],"balance_after":6555,"derivative":{"exercise_price":11.81,"expiration_date":"2034-02-27","underlying":"Class A Common Stock","underlying_shares":4055},"source":{"system":"sec-edgar","filing":"0001641489-24-000042","document":"wk-form4_1718311314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000042/wk-form4_1718311314.xml","form_type":"4"}},{"id":1480406,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":2147,"kind":"person","name":"SEKHRI PAUL J","position":1,"cik":"0001264519","reported_name":"SEKHRI PAUL J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee stock option (right to buy)","published_at":"2024-06-13T20:40:04.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":89212,"price":11.81,"value":1053593.72,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vests in equal quarterly installments over the three-year period beginning on February 27, 2024.  The option was conditioned upon shareholder approval of the 2024 Equity Incentive Plan, which was approved by the shareholders on June 11, 2024."}],"balance_after":144212,"derivative":{"exercise_price":11.81,"expiration_date":"2034-02-27","underlying":"Class A Common Stock","underlying_shares":89212},"source":{"system":"sec-edgar","filing":"0001641489-24-000040","document":"wk-form4_1718311197.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264519/000164148924000040/wk-form4_1718311197.xml","form_type":"4"}},{"id":1480665,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2024-06-13T20:37:01.000Z","date":"2024-03-13","kind":"grant","planned":false,"acquired":true,"shares":3750,"price":16.04,"value":60150.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly installments over the three-year period beginning March 13, 2024. The option was granted upon Dr. Phillips' appointment to the Board but was conditioned upon shareholder approval of the 2024 Equity Incentive Plan, which was approved by the shareholders on June 11, 2024."}],"balance_after":3750,"derivative":{"exercise_price":16.04,"expiration_date":"2034-03-13","underlying":"Class A Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001641489-24-000038","document":"wk-form4_1718311014.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000164148924000038/wk-form4_1718311014.xml","form_type":"4"}},{"id":1480971,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":89941,"kind":"person","name":"Tuch Steven L.","position":1,"cik":"0001957337","reported_name":"Tuch Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2024-06-13T16:38:28.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":62159,"price":11.81,"value":734097.79,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in quarterly equal installments over the three year period beginning on February 27, 2024.  The option was conditioned upon shareholder approval of the 2024 Equity Incentive Plan, which was approved by the shareholders on June 11, 2024."}],"balance_after":74659,"derivative":{"exercise_price":11.81,"expiration_date":"2034-02-27","underlying":"Class A Common Stock","underlying_shares":62159},"source":{"system":"sec-edgar","filing":"0001641489-24-000039","document":"wk-form4_1718311099.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1957337/000164148924000039/wk-form4_1718311099.xml","form_type":"4"}},{"id":1589861,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Prefunded Warrants","published_at":"2024-03-07T21:53:02.000Z","date":"2024-03-05","kind":"grant","planned":false,"acquired":true,"shares":52925,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 5, 2024, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") entered into an exchange agreement (\"Exchange Agreement\") with vTv Therapeutics Inc. (the \"Issuer\") pursuant to which the Issuer exchanged 4,776 and 52,881 shares of Class A common stock of the Issuer (\"Common Stock\"), respectively, for 4,780 and 52,925 warrants to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\"), respectively."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 5, 2024, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") entered into an exchange agreement (\"Exchange Agreement\") with vTv Therapeutics Inc. (the \"Issuer\") pursuant to which the Issuer exchanged 4,776 and 52,881 shares of Class A common stock of the Issuer (\"Common Stock\"), respectively, for 4,780 and 52,925 warrants to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\"), respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the \"Beneficial Ownership Limitation\"). The Prefunded Warrants have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"By written notice to the Issuer, 667 and Life Sciences may increase or decrease the Beneficial Ownership Limitation applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the \"Beneficial Ownership Limitation\"). The Prefunded Warrants have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On March 5, 2024, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") entered into an exchange agreement (\"Exchange Agreement\") with vTv Therapeutics Inc. (the \"Issuer\") pursuant to which the Issuer exchanged 4,776 and 52,881 shares of Class A common stock of the Issuer (\"Common Stock\"), respectively, for 4,780 and 52,925 warrants to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\"), respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I or securities reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":2823061,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":52925},"source":{"system":"sec-edgar","filing":"0000950170-24-028107","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017024028107/ownership.xml","form_type":"4"}},{"id":1589860,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Prefunded Warrants","published_at":"2024-03-07T21:53:02.000Z","date":"2024-03-05","kind":"grant","planned":false,"acquired":true,"shares":4780,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 5, 2024, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") entered into an exchange agreement (\"Exchange Agreement\") with vTv Therapeutics Inc. (the \"Issuer\") pursuant to which the Issuer exchanged 4,776 and 52,881 shares of Class A common stock of the Issuer (\"Common Stock\"), respectively, for 4,780 and 52,925 warrants to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\"), respectively."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 5, 2024, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") entered into an exchange agreement (\"Exchange Agreement\") with vTv Therapeutics Inc. (the \"Issuer\") pursuant to which the Issuer exchanged 4,776 and 52,881 shares of Class A common stock of the Issuer (\"Common Stock\"), respectively, for 4,780 and 52,925 warrants to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\"), respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the \"Beneficial Ownership Limitation\"). The Prefunded Warrants have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"By written notice to the Issuer, 667 and Life Sciences may increase or decrease the Beneficial Ownership Limitation applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the \"Beneficial Ownership Limitation\"). The Prefunded Warrants have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On March 5, 2024, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") entered into an exchange agreement (\"Exchange Agreement\") with vTv Therapeutics Inc. (the \"Issuer\") pursuant to which the Issuer exchanged 4,776 and 52,881 shares of Class A common stock of the Issuer (\"Common Stock\"), respectively, for 4,780 and 52,925 warrants to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\"), respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I or securities reported in column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is\nBaker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":254948,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":4780},"source":{"system":"sec-edgar","filing":"0000950170-24-028107","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017024028107/ownership.xml","form_type":"4"}},{"id":1589859,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-07T21:53:02.000Z","date":"2024-03-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":52881,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 5, 2024, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") entered into an exchange agreement (\"Exchange Agreement\") with vTv Therapeutics Inc. (the \"Issuer\") pursuant to which the Issuer exchanged 4,776 and 52,881 shares of Class A common stock of the Issuer (\"Common Stock\"), respectively, for 4,780 and 52,925 warrants to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\"), respectively."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 5, 2024, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") entered into an exchange agreement (\"Exchange Agreement\") with vTv Therapeutics Inc. (the \"Issuer\") pursuant to which the Issuer exchanged 4,776 and 52,881 shares of Class A common stock of the Issuer (\"Common Stock\"), respectively, for 4,780 and 52,925 warrants to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\"), respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On March 5, 2024, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") entered into an exchange agreement (\"Exchange Agreement\") with vTv Therapeutics Inc. (the \"Issuer\") pursuant to which the Issuer exchanged 4,776 and 52,881 shares of Class A common stock of the Issuer (\"Common Stock\"), respectively, for 4,780 and 52,925 warrants to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\"), respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I or securities reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":89254,"source":{"system":"sec-edgar","filing":"0000950170-24-028107","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017024028107/ownership.xml","form_type":"4"}},{"id":1589858,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-07T21:53:02.000Z","date":"2024-03-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4776,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 5, 2024, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") entered into an exchange agreement (\"Exchange Agreement\") with vTv Therapeutics Inc. (the \"Issuer\") pursuant to which the Issuer exchanged 4,776 and 52,881 shares of Class A common stock of the Issuer (\"Common Stock\"), respectively, for 4,780 and 52,925 warrants to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\"), respectively."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 5, 2024, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") entered into an exchange agreement (\"Exchange Agreement\") with vTv Therapeutics Inc. (the \"Issuer\") pursuant to which the Issuer exchanged 4,776 and 52,881 shares of Class A common stock of the Issuer (\"Common Stock\"), respectively, for 4,780 and 52,925 warrants to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\"), respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On March 5, 2024, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") entered into an exchange agreement (\"Exchange Agreement\") with vTv Therapeutics Inc. (the \"Issuer\") pursuant to which the Issuer exchanged 4,776 and 52,881 shares of Class A common stock of the Issuer (\"Common Stock\"), respectively, for 4,780 and 52,925 warrants to purchase Common Stock at an exercise price of $0.01 per share with no expiration date (\"Prefunded Warrants\"), respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I or securities reported in column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is\nBaker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":8060,"source":{"system":"sec-edgar","filing":"0000950170-24-028107","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017024028107/ownership.xml","form_type":"4"}},{"id":1609708,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre- Funded Warrants (Right to Buy)","published_at":"2024-03-01T00:33:01.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":833693,"price":11.8,"value":9837577.4,"ownership":{"direct":false,"nature":"Samsara BioCapital, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held by Samsara BioCapital, L.P. (\"Samsara LP\"). Samsara BioCapital GP, LLC (\"Samsara LLC\") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein."}],"balance_after":833693,"derivative":{"exercise_price":0.01,"underlying":"Class A Common Stock","underlying_shares":833693},"source":{"system":"sec-edgar","filing":"0001415889-24-005996","document":"form4-03012024_120353.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253170/000141588924005996/form4-03012024_120353.xml","form_type":"4"}},{"id":1609707,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2024-03-01T00:33:01.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":224732,"price":11.81,"value":2654084.92,"ownership":{"direct":false,"nature":"By Samsara BioCapital, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held by Samsara BioCapital, L.P. (\"Samsara LP\"). Samsara BioCapital GP, LLC (\"Samsara LLC\") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein."}],"balance_after":265620,"source":{"system":"sec-edgar","filing":"0001415889-24-005996","document":"form4-03012024_120353.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253170/000141588924005996/form4-03012024_120353.xml","form_type":"4"}},{"id":1847608,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":26244,"kind":"person","name":"FRY JOHN A","position":1,"cik":"0001255140","reported_name":"FRY JOHN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2023-06-21T20:22:20.000Z","date":"2023-06-19","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one-year anniversary of the date of grant."}],"balance_after":75000,"derivative":{"exercise_price":0.8,"exercise_date":"2024-06-19","expiration_date":"2033-06-19","underlying":"Class A Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001641489-23-000038","document":"wk-form4_1687378930.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1255140/000164148923000038/wk-form4_1687378930.xml","form_type":"4"}},{"id":1847482,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34739,"kind":"person","name":"Al-Marzooqi Fahed","position":1,"cik":"0001928247","reported_name":"Al-Marzooqi Fahed","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2023-06-21T20:21:03.000Z","date":"2023-06-19","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one-year anniversary of the date of grant."}],"balance_after":75000,"derivative":{"exercise_price":0.8,"exercise_date":"2024-06-19","expiration_date":"2033-06-19","underlying":"Class A Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001641489-23-000036","document":"wk-form4_1687378854.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000036/wk-form4_1687378854.xml","form_type":"4"}},{"id":1847481,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":112045,"kind":"person","name":"Harjivan Chandresh","position":1,"cik":"0001932607","reported_name":"Harjivan Chandresh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2023-06-21T20:19:41.000Z","date":"2023-06-19","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one-year anniversary of the date of grant."}],"balance_after":75000,"derivative":{"exercise_price":0.8,"exercise_date":"2024-06-19","expiration_date":"2033-06-19","underlying":"Class A Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001641489-23-000034","document":"wk-form4_1687378770.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000034/wk-form4_1687378770.xml","form_type":"4"}},{"id":1847480,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":38185,"kind":"person","name":"Harris Keith R.","position":1,"cik":"0001742703","reported_name":"Harris Keith R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2023-06-21T20:18:12.000Z","date":"2023-06-19","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one-year anniversary of the date of grant."}],"balance_after":75000,"derivative":{"exercise_price":0.8,"exercise_date":"2024-06-19","expiration_date":"2033-06-19","underlying":"Class A Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001641489-23-000032","document":"wk-form4_1687378681.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000032/wk-form4_1687378681.xml","form_type":"4"}},{"id":1847643,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":43481,"kind":"person","name":"KOZLOV HERSH","position":1,"cik":"0001228774","reported_name":"KOZLOV HERSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2023-06-21T20:15:21.000Z","date":"2023-06-19","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one-year anniversary of the date of grant."}],"balance_after":75000,"derivative":{"exercise_price":0.8,"exercise_date":"2024-06-19","expiration_date":"2033-06-19","underlying":"Class A Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001641489-23-000028","document":"wk-form4_1687378498.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228774/000164148923000028/wk-form4_1687378498.xml","form_type":"4"}},{"id":1847874,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":112059,"kind":"person","name":"Weiner Howard L.","position":1,"cik":"0001710056","reported_name":"Weiner Howard L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2023-06-21T16:16:53.000Z","date":"2023-06-19","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one-year anniversary of the date of grant."}],"balance_after":75000,"derivative":{"exercise_price":0.8,"exercise_date":"2024-06-19","expiration_date":"2033-06-19","underlying":"Class A Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001641489-23-000030","document":"wk-form4_1687378603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710056/000164148923000030/wk-form4_1687378603.xml","form_type":"4"}},{"id":2088274,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":89941,"kind":"person","name":"Tuch Steven L.","position":1,"cik":"0001957337","reported_name":"Tuch Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Director stock option (right to buy)","published_at":"2022-12-13T17:02:20.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"An option to purchase 166,666 shares vests on December 12, 2023, and the remaining option to purchase 333,334 shares vests in equal quarterly installments over the two-year period beginning on December 12, 2023, subject to continued employment."}],"balance_after":500000,"derivative":{"exercise_price":0.8,"expiration_date":"2032-12-12","underlying":"Class A Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000950142-22-003352","document":"es220312566_4-tuch.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1957337/000095014222003352/es220312566_4-tuch.xml","form_type":"4"}},{"id":2101308,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":26244,"kind":"person","name":"FRY JOHN A","position":1,"cik":"0001255140","reported_name":"FRY JOHN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2022-12-01T02:45:39.000Z","date":"2022-11-29","kind":"purchase","acquired":true,"shares":40461,"price":0.8347,"value":33772.7967,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.81 to $0.849, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":61000,"source":{"system":"sec-edgar","filing":"0000950142-22-003282","document":"es220309096_4-fry.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1255140/000095014222003282/es220309096_4-fry.xml","form_type":"4"}},{"id":2101307,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":26244,"kind":"person","name":"FRY JOHN A","position":1,"cik":"0001255140","reported_name":"FRY JOHN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2022-12-01T02:45:39.000Z","date":"2022-11-28","kind":"purchase","acquired":true,"shares":20539,"price":0.8262,"value":16969.3218,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.805 to $0.8487, inclusive. The reporting person undertakes to provide to vTv Therapeutics Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":20539,"source":{"system":"sec-edgar","filing":"0000950142-22-003282","document":"es220309096_4-fry.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1255140/000095014222003282/es220309096_4-fry.xml","form_type":"4"}},{"id":2179065,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":112046,"kind":"person","name":"Isaacsohn Jonathan","position":1,"cik":"0001943095","reported_name":"Isaacsohn Jonathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2022-08-18T23:04:03.000Z","date":"2022-08-17","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests on August 9, 2023."}],"balance_after":50000,"derivative":{"exercise_price":1.29,"exercise_date":"2023-08-09","expiration_date":"2032-08-12","underlying":"Class A Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950142-22-002566","document":"es220280057_4-isaacsohn.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000095014222002566/es220280057_4-isaacsohn.xml","form_type":"4"}},{"id":2180635,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":38185,"kind":"person","name":"Harris Keith R.","position":1,"cik":"0001742703","reported_name":"Harris Keith R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2022-08-17T13:41:04.000Z","date":"2022-07-13","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests on July 13, 2023."}],"balance_after":25000,"derivative":{"exercise_price":0.69,"exercise_date":"2023-07-13","expiration_date":"2032-07-13","underlying":"Class A Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950142-22-002548","document":"es220270159_4-harris.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000095014222002548/es220270159_4-harris.xml","form_type":"4"}},{"id":2206784,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34739,"kind":"person","name":"Al-Marzooqi Fahed","position":1,"cik":"0001928247","reported_name":"Al-Marzooqi Fahed","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2022-07-15T20:40:21.000Z","date":"2022-07-13","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests on July 13, 2023."}],"balance_after":25000,"derivative":{"exercise_price":0.69,"exercise_date":"2023-07-13","expiration_date":"2032-07-13","underlying":"Class A Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950142-22-002216","document":"es220270155_4-almarzooqi.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000095014222002216/es220270155_4-almarzooqi.xml","form_type":"4"}},{"id":2211589,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":43481,"kind":"person","name":"KOZLOV HERSH","position":1,"cik":"0001228774","reported_name":"KOZLOV HERSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2022-07-06T20:13:54.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":105128,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"An option to purchase 80,128 shares vested immediately on July 1, 2022. The remaining option to purchase 25,000 shares vests on June 1, 2023."}],"balance_after":105128,"derivative":{"exercise_price":0.72,"expiration_date":"2032-07-01","underlying":"Class A Common Stock","underlying_shares":105128},"source":{"system":"sec-edgar","filing":"0000950142-22-002107","document":"es220267481_4-kozlov.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228774/000095014222002107/es220267481_4-kozlov.xml","form_type":"4"}},{"id":2211282,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":112045,"kind":"person","name":"Harjivan Chandresh","position":1,"cik":"0001932607","reported_name":"Harjivan Chandresh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2022-07-06T20:13:36.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests on June 1, 2023."}],"balance_after":25000,"derivative":{"exercise_price":0.72,"exercise_date":"2023-06-01","expiration_date":"2032-07-01","underlying":"Class A Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950142-22-002106","document":"es220267480_4-harjivan.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000095014222002106/es220267480_4-harjivan.xml","form_type":"4"}},{"id":2211536,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":26244,"kind":"person","name":"FRY JOHN A","position":1,"cik":"0001255140","reported_name":"FRY JOHN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2022-07-06T20:12:58.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":137077,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"An option to purchase 80,128 shares vested immediately on July 1, 2022. The remaining option to purchase 56,949 shares vests on June 1, 2023."}],"balance_after":137077,"derivative":{"exercise_price":0.72,"expiration_date":"2032-07-01","underlying":"Class A Common Stock","underlying_shares":137077},"source":{"system":"sec-edgar","filing":"0000950142-22-002105","document":"es220267479_4-fry.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1255140/000095014222002105/es220267479_4-fry.xml","form_type":"4"}},{"id":2212053,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":112059,"kind":"person","name":"Weiner Howard L.","position":1,"cik":"0001710056","reported_name":"Weiner Howard L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2022-07-06T16:14:24.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":105128,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"An option to purchase 80,128 shares vested immediately on July 1, 2022. The remaining option to purchase 25,000 shares vests on June 1, 2023."}],"balance_after":105128,"derivative":{"exercise_price":0.72,"expiration_date":"2032-07-01","underlying":"Class A Common Stock","underlying_shares":105128},"source":{"system":"sec-edgar","filing":"0000950142-22-002108","document":"es220267482_4-weiner.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710056/000095014222002108/es220267482_4-weiner.xml","form_type":"4"}},{"id":2349528,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":129493,"kind":"person","name":"Nelson Rich S.","position":1,"cik":"0001833145","reported_name":"Nelson Rich S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting Chief Executive Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2022-03-05T01:51:39.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"125,000 of the options vested on the date of grant and the remaining 375,000 options vest quarterly at rate of 31,250 every three months over three years beginning from March 1, 2022 subject to continued services as an employee or director."}],"balance_after":500000,"derivative":{"exercise_price":0.806,"expiration_date":"2032-03-03","underlying":"Class A common stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000950142-22-000901","document":"es220231439_4-nelson.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000095014222000901/es220231439_4-nelson.xml","form_type":"4"}},{"id":2462233,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":122511,"kind":"person","name":"PERELMAN RONALD O","position":1,"cik":"0001186472","reported_name":"PERELMAN RONALD O","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-12-21T16:51:47.000Z","date":"2021-12-20","kind":"sale","acquired":false,"shares":87000,"price":1.15,"value":100050.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The ROP Revocable Trust dated 1/9/2018 (the \"ROP Revocable Trust\"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated (\"M&F Inc.\"), which is the parent of MFV Holdings One LLC (\"MFV\") and MacAndrews & Forbes LLC (\"M&F LLC\"), which is the parent of MacAndrews & Forbes Group LLC (\"M&F Group\"). The ROP Revocable Trust is also the sole stockholder of Thirty Six East Corporation (\"Thirty Six East\"). M&F Group, MFV and Thirty Six East hold the securities described above. (cont'd on FN 2)"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(cont'd from FN 1) Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group, MFV and Thirty Six East may be deemed to be directors by deputization of vTv Therapeutics Inc. (the \"Issuer\") by virtue of the role of Rich Nelson, director of the Issuer, as Executive Vice President Corporate and Business Development of Vericast and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. (\"M&F TTP\"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC."}],"balance_after":36519212,"source":{"system":"sec-edgar","filing":"0000950142-21-004124","document":"es210212345_4-perelman.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1186472/000095014221004124/es210212345_4-perelman.xml","form_type":"4"}},{"id":2537114,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":78563,"kind":"person","name":"Prasad Deepa","position":1,"cik":"0001867165","reported_name":"Prasad Deepa","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee stock option (right to buy)","published_at":"2021-10-21T20:38:15.000Z","date":"2021-10-19","kind":"grant","acquired":true,"shares":2498635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options were granted as part of an inducement award and will vest on October 19, 2024 subject to continued employment (or earlier, upon achievement of certain performance measures)."}],"balance_after":2498635,"derivative":{"exercise_price":1.47,"expiration_date":"2031-10-19","underlying":"Class A common stock","underlying_shares":2498635},"source":{"system":"sec-edgar","filing":"0000950142-21-003262","document":"es210194007_4-prasad.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000095014221003262/es210194007_4-prasad.xml","form_type":"4"}},{"id":2726564,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":28385,"kind":"person","name":"Spiegel Noel Joseph","position":1,"cik":"0001513234","reported_name":"Spiegel Noel Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2021-05-05T20:42:09.000Z","date":"2021-05-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly installments over the three year period beginning May 3, 2021."}],"balance_after":115000,"derivative":{"exercise_price":2.54,"expiration_date":"2031-05-03","underlying":"Class A Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001562180-21-003228","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513234/000156218021003228/primarydocument.xml","form_type":"4"}},{"id":2726858,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":43481,"kind":"person","name":"KOZLOV HERSH","position":1,"cik":"0001228774","reported_name":"KOZLOV HERSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2021-05-05T20:41:58.000Z","date":"2021-05-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly installments over the three year period beginning May 3, 2021."}],"balance_after":41250,"derivative":{"exercise_price":2.54,"expiration_date":"2031-05-03","underlying":"Class A Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001562180-21-003227","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228774/000156218021003227/primarydocument.xml","form_type":"4"}},{"id":2726815,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":26244,"kind":"person","name":"FRY JOHN A","position":1,"cik":"0001255140","reported_name":"FRY JOHN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2021-05-05T20:41:45.000Z","date":"2021-05-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly installments over the three year period beginning May 3, 2021."}],"balance_after":92500,"derivative":{"exercise_price":2.54,"expiration_date":"2031-05-03","underlying":"Class A Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001562180-21-003226","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1255140/000156218021003226/primarydocument.xml","form_type":"4"}},{"id":2727406,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":112059,"kind":"person","name":"Weiner Howard L.","position":1,"cik":"0001710056","reported_name":"Weiner Howard L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2021-05-05T16:42:01.000Z","date":"2021-05-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly installments over the three year period beginning May 3, 2021."}],"balance_after":71250,"derivative":{"exercise_price":2.54,"expiration_date":"2031-05-03","underlying":"Class A Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001562180-21-003229","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710056/000156218021003229/primarydocument.xml","form_type":"4"}},{"id":2818705,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":129493,"kind":"person","name":"Nelson Rich S.","position":1,"cik":"0001833145","reported_name":"Nelson Rich S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2021-03-02T21:03:57.000Z","date":"2021-02-26","kind":"purchase","acquired":true,"shares":10000,"price":2.86,"value":28600.0,"ownership":{"direct":false,"nature":"By spouse as UTMA custodian for son."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held of record by the Reporting Person's spouse as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001562180-21-001764","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000156218021001764/primarydocument.xml","form_type":"4"}},{"id":2818704,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":129493,"kind":"person","name":"Nelson Rich S.","position":1,"cik":"0001833145","reported_name":"Nelson Rich S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2021-03-02T21:03:57.000Z","date":"2021-02-26","kind":"purchase","acquired":true,"shares":50000,"price":2.86,"value":143000.0,"ownership":{"direct":true},"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001562180-21-001764","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000156218021001764/primarydocument.xml","form_type":"4"}},{"id":2819387,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":43481,"kind":"person","name":"KOZLOV HERSH","position":1,"cik":"0001228774","reported_name":"KOZLOV HERSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2021-03-02T21:03:32.000Z","date":"2021-02-26","kind":"purchase","acquired":true,"shares":10000,"price":2.74,"value":27400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.7298 to $2.7399, inclusive. The reporting person undertakes to provide to vTv Therapeutics Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001562180-21-001762","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228774/000156218021001762/primarydocument.xml","form_type":"4"}},{"id":2939718,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":122511,"kind":"person","name":"PERELMAN RONALD O","position":1,"cik":"0001186472","reported_name":"PERELMAN RONALD O","relationship":{"ten_percent_owner":true}}],"security":"Call Option (right to buy)","published_at":"2020-12-17T17:02:21.000Z","date":"2020-12-17","kind":"other","acquired":false,"shares":1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 23, 2019, M&F Group entered into a letter agreement (the \"Letter Agreement\"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the \"Investment Period\"), the Issuer's Class A common stock, par value $0.01 per share (\"Common Stock\"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 17, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 23, 2019, M&F Group entered into a letter agreement (the \"Letter Agreement\"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the \"Investment Period\"), the Issuer's Class A common stock, par value $0.01 per share (\"Common Stock\"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 17, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 23, 2019, M&F Group entered into a letter agreement (the \"Letter Agreement\"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the \"Investment Period\"), the Issuer's Class A common stock, par value $0.01 per share (\"Common Stock\"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 17, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The ROP Revocable Trust dated 1/9/2018 (the \"ROP Revocable Trust\"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated (\"M&F Inc.\"), which is the parent of MFV Holdings One LLC (\"MFV\") and MacAndrews & Forbes LLC (\"M&F LLC\"), which is the parent of MacAndrews & Forbes Group LLC (\"M&F Group\"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the \"Issuer\") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. (\"M&F TTP\"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC."}],"balance_after":1,"derivative":{"exercise_price":1.6,"exercise_date":"2019-12-23","expiration_date":"2020-12-23","underlying":"Class A common stock","underlying_shares":625000},"source":{"system":"sec-edgar","filing":"0001140361-20-028743","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1186472/000114036120028743/form4.xml","form_type":"4"}},{"id":2939717,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":122511,"kind":"person","name":"PERELMAN RONALD O","position":1,"cik":"0001186472","reported_name":"PERELMAN RONALD O","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2020-12-17T17:02:21.000Z","date":"2020-12-17","kind":"purchase","acquired":true,"shares":625000,"price":1.6,"value":1000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The ROP Revocable Trust dated 1/9/2018 (the \"ROP Revocable Trust\"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated (\"M&F Inc.\"), which is the parent of MFV Holdings One LLC (\"MFV\") and MacAndrews & Forbes LLC (\"M&F LLC\"), which is the parent of MacAndrews & Forbes Group LLC (\"M&F Group\"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the \"Issuer\") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. (\"M&F TTP\"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC."}],"balance_after":36606212,"source":{"system":"sec-edgar","filing":"0001140361-20-028743","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1186472/000114036120028743/form4.xml","form_type":"4"}},{"id":2949913,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":122511,"kind":"person","name":"PERELMAN RONALD O","position":1,"cik":"0001186472","reported_name":"PERELMAN RONALD O","relationship":{"ten_percent_owner":true}}],"security":"Call Option (right to buy)","published_at":"2020-12-10T16:45:32.000Z","date":"2020-12-10","kind":"other","acquired":false,"shares":1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 23, 2019, M&F Group entered into a letter agreement (the \"Letter Agreement\"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the \"Investment Period\"), the Issuer's Class A common stock, par value $0.01 per share (\"Common Stock\"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 10, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 23, 2019, M&F Group entered into a letter agreement (the \"Letter Agreement\"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the \"Investment Period\"), the Issuer's Class A common stock, par value $0.01 per share (\"Common Stock\"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 10, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 23, 2019, M&F Group entered into a letter agreement (the \"Letter Agreement\"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the \"Investment Period\"), the Issuer's Class A common stock, par value $0.01 per share (\"Common Stock\"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 10, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The ROP Revocable Trust dated 1/9/2018 (the \"ROP Revocable Trust\"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated (\"M&F Inc.\"), which is the parent of MFV Holdings One LLC (\"MFV\") and MacAndrews & Forbes LLC (\"M&F LLC\"), which is the parent of MacAndrews & Forbes Group LLC (\"M&F Group\"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the \"Issuer\") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. (\"M&F TTP\"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC."}],"balance_after":1,"derivative":{"exercise_price":1.6,"exercise_date":"2019-12-23","expiration_date":"2020-12-23","underlying":"Class A common stock","underlying_shares":625000},"source":{"system":"sec-edgar","filing":"0001140361-20-028037","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1186472/000114036120028037/form4.xml","form_type":"4"}},{"id":2949912,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":122511,"kind":"person","name":"PERELMAN RONALD O","position":1,"cik":"0001186472","reported_name":"PERELMAN RONALD O","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2020-12-10T16:45:32.000Z","date":"2020-12-10","kind":"purchase","acquired":true,"shares":625000,"price":1.6,"value":1000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The ROP Revocable Trust dated 1/9/2018 (the \"ROP Revocable Trust\"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated (\"M&F Inc.\"), which is the parent of MFV Holdings One LLC (\"MFV\") and MacAndrews & Forbes LLC (\"M&F LLC\"), which is the parent of MacAndrews & Forbes Group LLC (\"M&F Group\"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the \"Issuer\") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. (\"M&F TTP\"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC."}],"balance_after":35981212,"source":{"system":"sec-edgar","filing":"0001140361-20-028037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1186472/000114036120028037/form4.xml","form_type":"4"}},{"id":2951156,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":144773,"kind":"person","name":"Holcombe Stephen L.","position":1,"cik":"0001648953","reported_name":"Holcombe Stephen L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee stock option (right to buy)","published_at":"2020-12-09T21:16:16.000Z","date":"2020-12-07","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three equal annual installments beginning on December 7, 2021."}],"balance_after":945579,"derivative":{"exercise_price":2.07,"expiration_date":"2030-12-07","underlying":"Class A Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001562180-20-007125","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641489/000156218020007125/primarydocument.xml","form_type":"4"}},{"id":2952084,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":117390,"kind":"person","name":"HOWARD RUDY","position":1,"cik":"0001108161","reported_name":"HOWARD RUDY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Secretary"}}],"security":"Employee stock option (right to buy)","published_at":"2020-12-09T16:16:28.000Z","date":"2020-12-07","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three equal annual installments beginning on December 7, 2021."}],"balance_after":594914,"derivative":{"exercise_price":2.07,"expiration_date":"2030-12-07","underlying":"Class A Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001562180-20-007126","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108161/000156218020007126/primarydocument.xml","form_type":"4"}},{"id":2967749,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":122511,"kind":"person","name":"PERELMAN RONALD O","position":1,"cik":"0001186472","reported_name":"PERELMAN RONALD O","relationship":{"ten_percent_owner":true}}],"security":"Call Option (right to buy)","published_at":"2020-11-24T16:45:35.000Z","date":"2020-11-24","kind":"other","acquired":false,"shares":1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 23, 2019, M&F Group entered into a letter agreement (the \"Letter Agreement\"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the \"Investment Period\"), the Issuer's Class A common stock, par value $0.01 per share (\"Common Stock\"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On November 24, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 23, 2019, M&F Group entered into a letter agreement (the \"Letter Agreement\"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the \"Investment Period\"), the Issuer's Class A common stock, par value $0.01 per share (\"Common Stock\"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On November 24, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 23, 2019, M&F Group entered into a letter agreement (the \"Letter Agreement\"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the \"Investment Period\"), the Issuer's Class A common stock, par value $0.01 per share (\"Common Stock\"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On November 24, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The ROP Revocable Trust dated 1/9/2018 (the \"ROP Revocable Trust\"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated (\"M&F Inc.\"), which is the parent of MFV Holdings One LLC (\"MFV\") and MacAndrews & Forbes LLC (\"M&F LLC\"), which is the parent of MacAndrews & Forbes Group LLC (\"M&F Group\"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the \"Issuer\") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. (\"M&F TTP\"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC."}],"balance_after":1,"derivative":{"exercise_price":1.6,"exercise_date":"2019-12-23","expiration_date":"2020-12-23","underlying":"Class A common stock","underlying_shares":625000},"source":{"system":"sec-edgar","filing":"0001140361-20-026446","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1186472/000114036120026446/form4.xml","form_type":"4"}},{"id":2967748,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":122511,"kind":"person","name":"PERELMAN RONALD O","position":1,"cik":"0001186472","reported_name":"PERELMAN RONALD O","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2020-11-24T16:45:35.000Z","date":"2020-11-24","kind":"purchase","acquired":true,"shares":625000,"price":1.6,"value":1000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The ROP Revocable Trust dated 1/9/2018 (the \"ROP Revocable Trust\"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated (\"M&F Inc.\"), which is the parent of MFV Holdings One LLC (\"MFV\") and MacAndrews & Forbes LLC (\"M&F LLC\"), which is the parent of MacAndrews & Forbes Group LLC (\"M&F Group\"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the \"Issuer\") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. (\"M&F TTP\"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC."}],"balance_after":35356212,"source":{"system":"sec-edgar","filing":"0001140361-20-026446","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1186472/000114036120026446/form4.xml","form_type":"4"}},{"id":3110289,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":43481,"kind":"person","name":"KOZLOV HERSH","position":1,"cik":"0001228774","reported_name":"KOZLOV HERSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2020-06-15T20:26:19.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":26250,"price":2.65,"value":69562.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"An option to acquire 2,812 shares is immediately vested on June 11, 2020. The remaining portion of the option grant (an option to acquire 23,438 shares) vests in monthly equal installments over the three year period beginning on June 11, 2020."}],"balance_after":26250,"derivative":{"exercise_price":2.65,"expiration_date":"2030-06-11","underlying":"Class A common stock","underlying_shares":26250},"source":{"system":"sec-edgar","filing":"0001562180-20-004484","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228774/000156218020004484/primarydocument.xml","form_type":"4"}},{"id":3110773,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":16924,"kind":"person","name":"KINDLER JEFFREY B","position":1,"cik":"0001174454","reported_name":"KINDLER JEFFREY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2020-06-15T20:26:02.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":15000,"price":2.65,"value":39750.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly equal installments over the three year period beginning on June 11, 2020."}],"balance_after":78121,"derivative":{"exercise_price":2.65,"expiration_date":"2030-06-11","underlying":"Class A common stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001562180-20-004482","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1174454/000156218020004482/primarydocument.xml","form_type":"4"}},{"id":3110133,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":28385,"kind":"person","name":"Spiegel Noel Joseph","position":1,"cik":"0001513234","reported_name":"Spiegel Noel Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2020-06-15T20:25:52.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":15000,"price":2.65,"value":39750.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly equal installments over the three year period beginning on June 11, 2020."}],"balance_after":100000,"derivative":{"exercise_price":2.65,"expiration_date":"2030-06-11","underlying":"Class A common stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001562180-20-004481","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513234/000156218020004481/primarydocument.xml","form_type":"4"}},{"id":3110218,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":26244,"kind":"person","name":"FRY JOHN A","position":1,"cik":"0001255140","reported_name":"FRY JOHN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2020-06-15T20:25:43.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":15000,"price":2.65,"value":39750.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly installments over the three year period beginning June 11, 2020."}],"balance_after":77500,"derivative":{"exercise_price":2.65,"expiration_date":"2030-06-11","underlying":"Class A common stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001562180-20-004480","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1255140/000156218020004480/primarydocument.xml","form_type":"4"}},{"id":3110624,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":112059,"kind":"person","name":"Weiner Howard L.","position":1,"cik":"0001710056","reported_name":"Weiner Howard L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2020-06-15T16:26:10.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":15000,"price":2.65,"value":39750.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly installments over the three year period beginning June 11, 2020."}],"balance_after":56250,"derivative":{"exercise_price":2.65,"expiration_date":"2030-06-11","underlying":"Class A common stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001562180-20-004483","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710056/000156218020004483/primarydocument.xml","form_type":"4"}},{"id":3145183,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":43481,"kind":"person","name":"KOZLOV HERSH","position":1,"cik":"0001228774","reported_name":"KOZLOV HERSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2020-05-18T20:28:29.000Z","date":"2020-05-15","kind":"purchase","acquired":true,"shares":10000,"price":3,"value":30000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.94 to $3.01, inclusive. The reporting person undertakes to provide to vTv Therapeutics Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001562180-20-003677","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228774/000156218020003677/primarydocument.xml","form_type":"4"}},{"id":3152376,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":122511,"kind":"person","name":"PERELMAN RONALD O","position":1,"cik":"0001186472","reported_name":"PERELMAN RONALD O","relationship":{"ten_percent_owner":true}}],"security":"Call Option (right to buy)","published_at":"2020-05-12T16:32:46.000Z","date":"2020-05-12","kind":"other","acquired":false,"shares":1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 23, 2019, M&F Group entered into a letter agreement (the \"Letter Agreement\"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the \"Investment Period\"), the Issuer's Class A common stock, par value $0.01 per share (\"Common Stock\"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On May 12, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 23, 2019, M&F Group entered into a letter agreement (the \"Letter Agreement\"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the \"Investment Period\"), the Issuer's Class A common stock, par value $0.01 per share (\"Common Stock\"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On May 12, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 23, 2019, M&F Group entered into a letter agreement (the \"Letter Agreement\"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the \"Investment Period\"), the Issuer's Class A common stock, par value $0.01 per share (\"Common Stock\"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On May 12, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The ROP Revocable Trust dated 1/9/2018 (the \"ROP Revocable Trust\"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated (\"M&F Inc.\"), which is the parent of MFV Holdings One LLC (\"MFV\") and MacAndrews & Forbes LLC (\"M&F LLC\"), which is the parent of MacAndrews & Forbes Group LLC (\"M&F Group\"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the \"Issuer\") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. (\"M&F TTP\"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC."}],"balance_after":1,"derivative":{"exercise_price":1.6,"exercise_date":"2019-12-23","expiration_date":"2020-12-23","underlying":"Class A common stock","underlying_shares":625000},"source":{"system":"sec-edgar","filing":"0001140361-20-011442","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1186472/000114036120011442/form4.xml","form_type":"4"}},{"id":3152375,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":122511,"kind":"person","name":"PERELMAN RONALD O","position":1,"cik":"0001186472","reported_name":"PERELMAN RONALD O","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2020-05-12T16:32:46.000Z","date":"2020-05-12","kind":"purchase","acquired":true,"shares":625000,"price":1.6,"value":1000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The ROP Revocable Trust dated 1/9/2018 (the \"ROP Revocable Trust\"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated (\"M&F Inc.\"), which is the parent of MFV Holdings One LLC (\"MFV\") and MacAndrews & Forbes LLC (\"M&F LLC\"), which is the parent of MacAndrews & Forbes Group LLC (\"M&F Group\"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the \"Issuer\") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. (\"M&F TTP\"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC."}],"balance_after":34731212,"source":{"system":"sec-edgar","filing":"0001140361-20-011442","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1186472/000114036120011442/form4.xml","form_type":"4"}},{"id":3216110,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":16924,"kind":"person","name":"KINDLER JEFFREY B","position":1,"cik":"0001174454","reported_name":"KINDLER JEFFREY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-03-11T20:12:06.000Z","date":"2020-03-10","kind":"exercise","acquired":false,"shares":11667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of vTv Therapeutics Inc. Class A Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on March 10, 2017 and vest in three equal installments beginning March 10, 2018."}],"balance_after":0,"derivative":{"expiration_date":"2020-03-10","underlying":"Class A Common Stock","underlying_shares":11667},"source":{"system":"sec-edgar","filing":"0001562180-20-002397","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1174454/000156218020002397/primarydocument.xml","form_type":"4"}},{"id":3216109,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":16924,"kind":"person","name":"KINDLER JEFFREY B","position":1,"cik":"0001174454","reported_name":"KINDLER JEFFREY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2020-03-11T20:12:06.000Z","date":"2020-03-10","kind":"exercise","acquired":true,"shares":11667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Class A common stock issued upon vesting of 33.33% of the restricted stock units granted March 10, 2017."}],"balance_after":35000,"source":{"system":"sec-edgar","filing":"0001562180-20-002397","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1174454/000156218020002397/primarydocument.xml","form_type":"4"}},{"id":3248752,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":122511,"kind":"person","name":"PERELMAN RONALD O","position":1,"cik":"0001186472","reported_name":"PERELMAN RONALD O","relationship":{"ten_percent_owner":true}}],"security":"Call Option (right to buy)","published_at":"2020-02-25T16:30:30.000Z","date":"2020-02-25","kind":"other","acquired":false,"shares":1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 23, 2019, M&F Group entered into a letter agreement (the \"Letter Agreement\"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the \"Investment Period\"), the Issuer's Class A common stock, par value $0.01 per share (\"Common Stock\"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On February 25, 2020, the Issuer exercised its right to have M&F Group purchase 1,250,000 shares of Common Stock for a total purchase price of $2,000,000 in cash."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 23, 2019, M&F Group entered into a letter agreement (the \"Letter Agreement\"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the \"Investment Period\"), the Issuer's Class A common stock, par value $0.01 per share (\"Common Stock\"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On February 25, 2020, the Issuer exercised its right to have M&F Group purchase 1,250,000 shares of Common Stock for a total purchase price of $2,000,000 in cash."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 23, 2019, M&F Group entered into a letter agreement (the \"Letter Agreement\"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the \"Investment Period\"), the Issuer's Class A common stock, par value $0.01 per share (\"Common Stock\"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On February 25, 2020, the Issuer exercised its right to have M&F Group purchase 1,250,000 shares of Common Stock for a total purchase price of $2,000,000 in cash."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The ROP Revocable Trust dated 1/9/2018 (the \"ROP Revocable Trust\"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated (\"M&F Inc.\"), which is the parent of MFV Holdings One LLC (\"MFV\") and MacAndrews & Forbes LLC (\"M&F LLC\"), which is the parent of MacAndrews & Forbes Group LLC (\"M&F Group\"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the \"Issuer\") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. (\"M&F TTP\"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC."}],"balance_after":1,"derivative":{"exercise_price":1.6,"exercise_date":"2019-12-23","expiration_date":"2020-12-23","underlying":"Class A common stock","underlying_shares":1250000},"source":{"system":"sec-edgar","filing":"0001140361-20-004007","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1186472/000114036120004007/form4.xml","form_type":"4"}}],"next_cursor":"2020-02-25T16:30:30.000000Z,3248752"}